News
SVRA
2.610
-5.43%
-0.150
Weekly Report: what happened at SVRA last week (0303-0307)?
Weekly Report · 4d ago
Savara’s Innovative Testing and BLA Submission Drive Buy Rating Amid Market Growth Potential
TipRanks · 03/06 16:06
Savara Launches New Dried Blood Spot Test For APAP Diagnosis
NASDAQ · 03/06 14:34
Savara Announces U.S. Launch of the aPAP ClearPath™ Dried Blood Spot Test to Detect Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Barchart · 03/06 07:05
Savara Inc <SVRA.OQ> expected to post a loss of 11 cents a share - Earnings Preview
Reuters · 03/05 11:02
Savara Announces Participation in the Leerink Global Healthcare Conference
Barchart · 03/03 15:15
Weekly Report: what happened at SVRA last week (0224-0228)?
Weekly Report · 03/03 09:12
Savara Insiders Lose Out As Stock Sinks To US$2.56
Simply Wall St · 02/26 10:39
Weekly Report: what happened at SVRA last week (0217-0221)?
Weekly Report · 02/24 09:12
Weekly Report: what happened at SVRA last week (0210-0214)?
Weekly Report · 02/17 09:12
Savara Announces New Employment Inducement Grant
Barchart · 02/14 15:05
Weekly Report: what happened at SVRA last week (0203-0207)?
Weekly Report · 02/10 09:11
Weekly Report: what happened at SVRA last week (0127-0131)?
Weekly Report · 02/03 09:11
Savara’s Molgramostim: Strong Buy Rating Backed by Clinical and Real-World Evidence for aPAP Treatment
TipRanks · 01/30 18:45
Savara Announces A Manuscript Titled, "Long-Term Outcomes In Five Patients With Autoimmune Pulmonary Alveolar Proteinosis Treated With Molgramostim Inhalation Solution" Was Published Online In The Journal ERJ Open Research
Benzinga · 01/30 13:53
Savara Announces Manuscript on Long-Term Outcomes With Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Published in ERJ Open Research
Barchart · 01/30 07:39
Savara Announces Participation in Upcoming Healthcare Investor Conferences
Barchart · 01/29 15:05
Weekly Report: what happened at SVRA last week (0120-0124)?
Weekly Report · 01/27 09:12
Savara Sets 2025 Executive Bonus Targets
TipRanks · 01/23 21:36
Weekly Report: what happened at SVRA last week (0113-0117)?
Weekly Report · 01/20 09:11
More
Webull provides a variety of real-time SVRA stock news. You can receive the latest news about Savara Inc through multiple platforms. This information may help you make smarter investment decisions.
About SVRA
More
Savara Inc. is a clinical-stage biopharmaceutical company, which is focused on rare respiratory diseases. The Company’s lead program, molgramostim nebulizer solution (molgramostim), is an inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim is an inhaled formulation of recombinant human GM-CSF and is being developed for the treatment of aPAP. Molgramostim nebulizer solution is administered once daily by inhalation via a high efficiency nebulizer, the eFlow Nebulizer System (PARI Pharma GmbH). Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the accumulation of surfactant in the alveoli (or air sacs) of the lungs. The Company is engaged in the advancement of the molgramostim aPAP program and the Phase III IMPALA-2 clinical trial and outsourcing capital-intensive operations.